Studies How Egg-Stimulating Drug Protocols Affect Blood Clotting in Women With Infertility
Compares different ovarian stimulation protocols and their effect on clotting in infertile women.
Plain-language title generated from the registry record
Registry title: Ovarian Hyperstimulation and Fibrin Clot Properties.
Key facts
- Where
- Krakow, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT04166825, who can take part
Where in Poland
- Department of Gynecological Endocrinology Jagiellonian University Medical CollegeKrakow, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jagiellonian University
- Trial code
- NCT04166825
- Record updated
- 5 December 2025
- Original description
The impact evaluation of ovarian hyperstimulation on coagulation and fibrinolysis in infertile women.Read full original descriptionShow less
The Impact of Different Ovarian Hyperstimulation Protocols on Coagulation and Fibrinolysis.
The impact evaluation of ovarian hyperstimulation on coagulation and fibrinolysis in infertile women.
Comparative analysis between different ovarian stimulation protocols on thrombin formation and efficiency of fibrinolysis in women diagnosed with infertility.
Inclusion: infertility defined based on the WHO 2010 criteria.
Exclusion: oral contraceptives use within previous 3 months; dienogest therapy within 3 months until ART; the presence of known VTE risk factors, including obesity, recent major surgery with prolonged immobilization or trauma,; severe hypertension; diabetes mellitus; antiphospholipid syndrome,; known malignancy,; any chronic inflammatory diseases (e.g. rheumatoid arthritis); advanced chronic renal disease (estimated glomerular filtration rate [eGFR] <30 ml/min),; international normalized ratio (INR) more than 1.2 at the day of blood draw; ovarian involvement; thrombotic events in the medical history; deficiency of antithrombin, protein C or protein S,; pregnancy.